

Takeshi Nawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3816471/publications.pdf>

Version: 2024-02-01

16
papers

528
citations

1163117

8
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

592
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to pembrolizumab in a patient with primary lung adenocarcinoma originated from indium lung. <i>BMC Pulmonary Medicine</i> , 2021, 21, 107.	2.0	0
2	<p>Chronic Cough and Phlegm in Subjects Undergoing Comprehensive Health Examination in Japan “Survey of Chronic Obstructive Pulmonary Disease Patients Epidemiology in Japan (SCOPE-J)</p>.</p> International Journal of COPD, 2020, Volume 15, 765-773.	2.3	3
3	A case of ROS1 rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib. <i>Thoracic Cancer</i> , 2020, 11, 2063-2066.	1.9	2
4	Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study. <i>Anticancer Research</i> , 2020, 40, 957-964.	1.1	7
5	Detection of circulating tumor cells in patients with lung cancer using metallic microcavity array filter: A pilot study. <i>Molecular and Clinical Oncology</i> , 2020, 12, 278-283.	1.0	7
6	A population-based cohort study to evaluate the effectiveness of lung cancer screening using low-dose CT in Hitachi city, Japan. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 130-136.	1.3	39
7	Low-dose CT screening for lung cancer reduced lung cancer mortality in Hitachi City. <i>International Journal of Radiation Biology</i> , 2019, 95, 1441-1446.	1.8	14
8	Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation. <i>Anticancer Research</i> , 2018, 38, 5409-5415.	1.1	8
9	Acquired EGFR T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional Study. <i>Anticancer Research</i> , 2018, 38, 3145-3150.	1.1	16
10	Efficacy of first-line erlotinib in non-small cell lung cancer patients undergoing dose reduction and those with a low body surface area: A population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group. <i>Molecular and Clinical Oncology</i> , 2016, 4, 425-428.	1.0	2
11	S-1-containing chemotherapy for patients with non-small-cell lung cancer: A population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group. <i>Molecular and Clinical Oncology</i> , 2016, 4, 1025-1030.	1.0	3
12	Low-dose Computed Tomography Screening in Japan. <i>Journal of Thoracic Imaging</i> , 2015, 30, 108-114.	1.5	23
13	Erlotinib for elderly patients with non-small-cell lung cancer: Subset analysis from a population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group. <i>Molecular and Clinical Oncology</i> , 2013, 1, 828-832.	1.0	13
14	Long-term prognosis of patients with lung cancer detected on low-dose chest computed tomography screening. <i>Lung Cancer</i> , 2012, 75, 197-202.	2.0	24
15	A decrease in lung cancer mortality following the introduction of low-dose chest CT screening in Hitachi, Japan. <i>Lung Cancer</i> , 2012, 78, 225-228.	2.0	46
16	Lung Cancer Screening Using Low-Dose Spiral CT. <i>Chest</i> , 2002, 122, 15-20.	0.8	318